Sutro Biopharma (STRO) Free Cash Flow (2017 - 2025)

Sutro Biopharma has reported Free Cash Flow for 9 years, with the latest figure at -$26.6 million in Q4 2025.

• Quarterly Free Cash Flow rose 64.11% year-over-year to -$26.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$178.9 million (up 8.07% YoY) and the FY2025 annual result came in at -$178.9 million, up 8.07% from the prior year.
• Free Cash Flow rose to -$26.6 million in Q4 2025 per STRO's latest filing, from -$39.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $67.8 million in Q3 2022 and troughed at -$74.2 million in Q4 2024.
• A 5-year average of -$29.0 million and a median of -$32.0 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow surged 369.23% in 2022, then plunged 622.81% in 2024.
• Over 5 years, Free Cash Flow stood at -$34.7 million in 2021, then jumped by 35.61% to -$22.4 million in 2022, then jumped by 163.41% to $14.2 million in 2023, then slumped by 622.81% to -$74.2 million in 2024, then soared by 64.11% to -$26.6 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$26.6 million, -$39.7 million, and -$44.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.